Exhibit 99.1
Shire Pharmaceuticals Group plc |  |
FIRST QUARTER 2004 RESULTS CONFERENCE CALL TIMING AMENDMENT – 29th April
Basingstoke, UK – 19 April 2004– Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) as previously announced will report first quarter 2004 earnings on Thursday, 29 April 2004. In consideration of the amount of companies reporting on 29th April and in order to accommodate our shareholders and analysts worldwide, we have changed the timing of our conference call to 15:45 BST / 10:45 EST as stated below.
| Results announcement time: | 12:00 BST / 07:00 EST | ||
| Conference call time: | 15:45 BST / 10:45 EST |
Conference call:
Matthew Emmens, Chief Executive Officer; Angus Russell, Chief Financial Officer and Wilson Totten, Chief Scientific Officer will host the live conference call at 15:45 BST/10:45 EST.
Please RSVPclaire.rowell@fd.com (T: +44 (0)20 7269 7285).
Live conference call:
The details of the live conference call are as follows:
| UK dial in | +44 (0) 1452 569393 | ||
| US / Canada dial | +1 866 434 1089 | ||
| in | |||
| Password | Shire |
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible throughwww.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for 1 week. Details are as follows:
| UK dial in | +44 (0) 1452 550000 | ||
| Pin code | 1261750# | ||
| US dial in | +1 866 247 4222 | ||
| Pin code | 1261750# | ||
| Webcast Replay | www.shire.com, in the investor relations section |
If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160
End
For further information please contact:
Souheil Salah – Investor Relations +44 (0)1256 894 160
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website: www.shire.com.